Company intelligence / Profile preview
Zhejiang Shimai Pharmaceutical Co., Ltd.
Hangzhou, Zhejiang, Chinacentrymed.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has multiple programs in clinical development, with three products in Phase 2 clinical trials (CMD-011, SMET-12, DNV-3) and several others in preclinical and Phase 1 stages. Their lead candidates target various cancers including hepatocellular carcinoma, non-small cell lung cancer, and melanoma.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyBispecific antibodyBispecific T-cell Engager (BiTE)Trispecific antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Betta Pharmaceuticals Co., Ltd.
Beyond the preview
Go deeper on Zhejiang Shimai Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Shimai Pharmaceutical Co., Ltd..